12:49 AM EDT, 10/28/2026 (MT Newswires) -- RBC Capital Markets revised its model for Novartis (NOVN.SW), citing the Swiss pharmaceutical group's third-quarter performance and recent trends. "Solid 3Q26, albeit with older products driving the beat, and raised full-year guidance. Importantly, management remains confident in key growth drivers. Kisqali commands dominant early breast cancer share, now supported by OS data, while Kesimpta achieved 16% MS market share with 77% of US new patients in first-line/first-switch settings. On Pluvicto's weakness, we think consensus overlooked timing issues related to PET scan backlogs. This sets up well for the Meet-the-Management Event (Nov 18-19), where the team will detail pipeline timelines and opportunity sizing for post-2030 growth (cons: ~4% CAGR 2026-31E), which remains a key debate on the stock," analysts said Tuesday. Novartis reported a 4% year-over-year increase in net sales to $14.52 billion, driven primarily by brands including Kisqali, Kesimpta and Scemblix. The company raised its full-year 2026 core operating income guidance to low single-digit growth, from the previous expectation of a low single-digit decline. Against this backdrop, the research firm adjusted its 2026 revenue and EPS estimates to $56.2 billion and $8.89, respectively, from $56.3 billion and $8.75. For 2027, revenue is projected at $59.4 billion, down from the earlier $60.4 billion forecast, while EPS is expected to rise to $10.01 from $9.63. RBC raised the sector perform-rated stock's price target to 130 francs from 120 francs.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.